The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 03, 2015
Filed:
Jan. 23, 2014
Applicant:
University of Georgia Research Foundation, Inc., Athens, GA (US);
Inventor:
Chung K. Chu, Statham, GA (US);
Assignee:
University of Georgia Research Foundation, Inc., Athens, GA (US);
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/90 (2006.01); A61K 31/53 (2006.01); C07D 239/54 (2006.01); C07F 9/6512 (2006.01); A61K 31/513 (2006.01); A61K 45/06 (2006.01); A61K 31/675 (2006.01); C07F 9/6561 (2006.01); C07F 9/6574 (2006.01); C07F 9/24 (2006.01); A61K 31/404 (2006.01); A61K 31/7056 (2006.01); A61K 31/7088 (2006.01); A61K 38/06 (2006.01); A61K 38/08 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61K 39/42 (2006.01);
U.S. Cl.
CPC ...
C07D 239/54 (2013.01); C07F 9/65125 (2013.01); A61K 31/513 (2013.01); A61K 45/06 (2013.01); A61K 31/675 (2013.01); C07K 9/65586 (2013.01); C07F 9/65616 (2013.01); C07F 9/65744 (2013.01); C07F 9/2458 (2013.01); A61K 31/404 (2013.01); A61K 31/53 (2013.01); A61K 31/7056 (2013.01); A61K 31/7088 (2013.01); A61K 38/06 (2013.01); A61K 38/08 (2013.01); A61K 38/212 (2013.01); A61K 39/3955 (2013.01); A61K 39/42 (2013.01);
Abstract
Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity.